FDA Approves Farxiga (dapagliflozin) for Chronic Kidney Disease and Heart Failure
FDA approves Farxiga for chronic kidney disease and heart failure.
FDA approved Farxiga (dapagliflozin) to reduce risk of eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospi…
The FDA approved Farxiga to treat chronic kidney disease and heart failure in adults. It helps protect the kidneys and heart, even in people…
FDA Approves Steglujan (ertugliflozin/sitagliptin) for Type 2 Diabetes
FDA approves new combination pill for type 2 diabetes
FDA approved Steglujan (ertugliflozin/sitagliptin) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diab…
The FDA approved Steglujan, a pill that combines two diabetes drugs, to help control blood sugar in adults with type 2 diabetes. It is meant…
FDA Approves Steglatro (ertugliflozin) for Type 2 Diabetes Mellitus
FDA approves new diabetes drug Steglatro to lower blood sugar
FDA approved Steglatro (ertugliflozin) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The SG…
The FDA approved Steglatro (ertugliflozin) to improve blood sugar control in adults with type 2 diabetes. It is used along with diet and exe…
FDA Approves Invokana (canagliflozin) for Type 2 Diabetes and Related Conditions
FDA approves Invokana to treat type 2 diabetes and protect heart and kidneys.
FDA approved Invokana (canagliflozin) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It also…
The FDA has approved Invokana (canagliflozin) for adults with type 2 diabetes. It helps lower blood sugar and reduces risks of heart attack,…
Pancreaticoduodenectomy alters GLP-1 and GIP responses, exploratory meta-analysis finds
Early data suggest Whipple surgery may boost GLP-1 levels faster than pylorus-preserving options
This systematic review and exploratory meta-analysis of 134 participants found that pancreaticoduodenectomy generally increases GLP-1 levels…
A small analysis of two studies found that Whipple surgery might increase GLP-1 levels more quickly than pylorus-preserving procedures, thou…
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
MDT management of insulinoma in pregnancy yields partial glycaemic control but fetal growth restriction occurred in this case
Multidisciplinary care manages insulinoma in pregnancy with mixed fetal outcomes
This literature review presents a case report of a 36-year-old gravida 4 para 2 woman with insulinoma during pregnancy. The multidisciplinar…
A single case report shows partial blood sugar control with octreotide and fetal growth restriction after EUS-RFA for an insulinoma during p…
Review of ADSC-Exos for diabetic foot ulcers lacks reported efficacy data or safety outcomes in this narrative synthesis
Stem cell exosomes may help heal diabetic foot ulcers
This narrative review addresses the use of adipose-derived stem cell exosomes for diabetic foot ulcers and diabetes. The authors note that k…
A review suggests that exosomes from stem cells could improve healing for diabetic foot ulcers, offering a new treatment option.
Meta-analysis finds no link between early-life antibiotics and type 1 diabetes risk
Antibiotics in Pregnancy Don’t Raise Child’s Diabetes Risk, Study Finds
This meta-analysis of early-life antibiotic exposure found no significant association with type 1 diabetes incidence in the general populati…
This large review offers reassurance that standard antibiotic use during pregnancy and infancy is safe regarding type 1 diabetes risk, with …
Long-term voglibose use likely caused leukopenia in a 71-year-old man with type 2 diabetes
Switching diabetes drugs reversed low white blood cell counts in a 71-year-old man
This case report describes a 71-year-old male with well-controlled type 2 diabetes who developed leukopenia after long-term voglibose use. W…
A 71-year-old man with type 2 diabetes saw his white blood cell count rise after switching from voglibose to acarbose, suggesting the first …
Bile acid modifications and microbiota interventions show promise for metabolic and digestive diseases in preclinical models
Bile acid and microbiota changes may help treat several diseases
This narrative review examines bile acid modifications, microbiota interventions, and BA-targeted therapies for metabolic, digestive, hepato…
This review explores how changing bile acids and gut bacteria could treat metabolic, digestive, and liver diseases, but most evidence is fro…
Color Doppler ultrasound differentiates Graves' disease from silent thyroiditis in thyrotoxicosis patients
Ultrasound blood flow patterns help distinguish Graves' disease from silent thyroiditis
This single-center prospective observational cohort study of 78 adults with thyrotoxicosis found that color Doppler ultrasound (CDU) with th…
A new study finds that measuring thyroid blood flow with ultrasound can help tell Graves' disease apart from silent thyroiditis, a key diagn…